New Therapy Could Result in Weight Loss and Lower Glucose

Encouraging trial outcomes from Novo Nordisk present {that a} new mixture remedy in improvement might assist folks decrease their A1C and weight dramatically. With the upcoming launch of a number of bigger research investigating the brand new remedy, discover out if you happen to can take part in one in every of these trials.
Novo Nordisk introduced thrilling outcomes on Aug. 22 from a current medical trial that might probably result in a brand new remedy with important weight reduction and A1C reductions for folks with kind 2 diabetes.
Semaglutide and cagrilintide are mixed in the remedy being studied in medical trials. Semaglutide, generally identified underneath the model names Ozempic, Wegovy, and Rybelsus, are in a category of medicine known as GLP-1 receptor agonists, which have been proven to assist folks with kind 2 diabetes scale back their A1C and shed some pounds.
Cagrilintide is a sort of drug referred to as an amylin analogue. This signifies that it mimics the motion of amylin, a hormone produced by the pancreas that makes folks really feel “satiety,” or “fullness,” after consuming a meal. Cagrilintide doesn’t have a model identify, because it has not but been FDA authorized. However, one other amylin analogue, Symlin (pramlintide), is already authorized to be used by folks with kind 1 or kind 2 diabetes who use mealtime insulin and haven’t met their glucose administration targets regardless of optimum insulin remedy.
The mixture drug is presently being known as  “CagriSema” by the corporate. If profitable, it’ll ultimately have each a generic and model identify. 
Topline outcomes from a current part 2 trial with 90 individuals confirmed that folks handled with CagriSema had important reductions in each A1C and physique weight in comparison with these handled with every drug alone. Over the 32-week trial, individuals on CagriSema, on common, diminished their A1C by 2.2 share factors and misplaced 15.6% of their physique weight.
Compared to CagriSema, folks on semaglutide and cagrilintide alone had a median A1C discount of 1.8% and 0.9%, respectively, whereas their common weight reduction was 5.1% and 8.1%, respectively. The trial additionally measured the results of every remedy on Time in Range, as measured by a steady glucose monitor (CGM); nonetheless this information has not but been launched.
Novo Nordisk plans to launch a number of bigger part 3 research to analyze CagriSema,  collectively referred to as the REDEFINE program, in direction of the tip of 2022.
In the meantime, CagriSema is being investigated in a bigger part 2 trial for folks with non-alcoholic steatohepatitis (NASH), a sort of liver illness that could be a widespread complication of kind 2 diabetes. This trial hopes to enroll 672 individuals throughout over 130 places in the United States, Canada, Europe, and Asia.
To discover out extra concerning the actively-recruiting trial for CagriSema and liver illness, learn the web page or contact Novo Nordisk straight at [email protected] or name 1-866-867-7178.

What do you suppose?

Do you advocate this text?

About the authors

Andrew Briskin joined the diaTribe Foundation in 2021 after graduating from the University of Pennsylvania with a level in Health and Societies . Briskin is an Editor for diaTribe Learn….
Read the complete bio »

Recommended For You